CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma

(MedPage Today) -- CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) reduced the risk of disease progression or death compared with standard care in lenalidomide...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news